Literature DB >> 2613291

Enhancement of normal neutrophil chemiluminescence by chronic granulomatous disease neutrophils.

R L Roberts1, B J Ank, E R Stiehm.   

Abstract

Neutrophils and other phagocytic cells from patients with chronic granulomatous disease (CGD) lack the ability to generate reactive oxygen intermediates (ROI), although other phagocytic functions appear to be intact. The effects of CGD neutrophils on the ability of normal neutrophils to produce ROI as measured by luminol-enhanced chemiluminescence (CL) were examined. Normal neutrophils (2 x 10(5)) had a peak CL response to phorbol myristate acetate (PMA; 20 ng/ml) of 6.5 +/- 0.9 mV, while the CL response to CGD neutrophils was completely absent. However, the addition of CGD neutrophils (8 x 10(5)) to normal neutrophils (2 x 10(5)) markedly increased the peak CL response to PMA to 11.0 +/- 1.1 mV (P less than 0.001). The peak response of normal neutrophils (2 x 10(5)) alone to the peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP; 10(-6) M) was 9.0 +/- 1.1 mV, and this increased to 22.2 +/- 3.5 mV (P less than 0.001) when 8 x 10(5) CGD neutrophils were added and to 18.9 +/- 3.6 mV (P less than 0.005) when 4 x 10(5) CGD neutrophils were added. Thus, CGD neutrophils increase the release of ROI from normal cells, suggesting nonoxidative regulatory factors in ROI production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613291     DOI: 10.1007/bf00914307

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  23 in total

Review 1.  Chronic granulomatous disease.

Authors:  R B Johnston; S L Newman
Journal:  Pediatr Clin North Am       Date:  1977-05       Impact factor: 3.278

2.  Increasing extracellular potassium causes calcium-dependent shape change and facilitates concanavalin A capping in human neutrophils.

Authors:  R L Roberts; N L Mounessa; J I Gallin
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

3.  Studies of phagocytosis in chronic granulomatous disease.

Authors:  T A Gaither; S R Medley; J I Gallin; M M Frank
Journal:  Inflammation       Date:  1987-06       Impact factor: 4.092

4.  Comparison between luminol- and lucigenindependent chemiluminescence of polymorphonuclear leukocytes.

Authors:  H Aniansson; O Stendahl; C Dahlgren
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-12

5.  A mechanism for inhibition of luminol-dependent neutrophil chemiluminescence by polyanions.

Authors:  E P Brestel; E J McClain
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

6.  Classification of chronic granulomatous disease.

Authors:  J T Curnutte
Journal:  Hematol Oncol Clin North Am       Date:  1988-06       Impact factor: 3.722

7.  Clinical features and current management of chronic granulomatous disease.

Authors:  C B Forrest; J R Forehand; R A Axtell; R L Roberts; R B Johnston
Journal:  Hematol Oncol Clin North Am       Date:  1988-06       Impact factor: 3.722

8.  Stimulus-specific neutrophil aggregation: evaluation of possible mechanisms for the stimulus-response apparatus.

Authors:  B Ringertz; J Palmblad; J A Lindgren
Journal:  J Lab Clin Med       Date:  1985-08

Review 9.  Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies.

Authors:  A I Tauber; N Borregaard; E Simons; J Wright
Journal:  Medicine (Baltimore)       Date:  1983-09       Impact factor: 1.889

10.  Rapid method for isolation of normal human peripheral blood eosinophils on discontinuous Percoll gradients and comparison with neutrophils.

Authors:  R L Roberts; J I Gallin
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

View more
  1 in total

1.  Role of oxygen intermediates in cytotoxicity: studies in chronic granulomatous disease.

Authors:  R L Roberts; B J Ank; M W Fanger; L Shen; E R Stiehm
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.